Adipocytokines in nonalcoholic fatty liver disease: Key players regulating steatosis, inflammation and fibrosis

Current Pharmaceutical Design

Volumn 16, Issue 17, 2010, Pages 1893-1894

  Tilg, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cytokines; Fatty liver disease; Inflammation; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR; FAT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRE B CELL ENHANCING FACTOR; RESISTIN; RETINOL BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE;

CYTOKINE RELEASE; EDITORIAL; GLUCOSE BLOOD LEVEL; HEPATITIS; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FATTY DEGENERATION; LIVER FIBROSIS; NECROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; STEATOSIS; ANIMAL; COMPLICATION; FATTY LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOPHYSIOLOGY;

ADIPOKINES; ADIPONECTIN; ANIMALS; CYTOKINES; FATTY LIVER; HUMANS; INFLAMMATION; LEPTIN; LIVER CIRRHOSIS; OBESITY; OXIDATIVE STRESS;

EID: 77953496579     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791208929     Document Type: Editorial

References (35)

1. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-89.
2. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009; 25: 230-7.
3. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
4. Hotamisligil GS. Inflammation & metabolic disorders. Nature 2006; 444: 860-7
5. Fan JG. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis 2008; 9: 63-7.
6. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology 2010; 51: 373-5.
7. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
8. [8] Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; CD007340.
9. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-9.
10. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83.
11. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009; 30: 234-9.
12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
13. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-9.
14. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-9.
15. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-7.
16. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630-35.
17. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-9.
18. Kim JY, van de WE, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117: 2621-37.
19. Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100: 2438-46.
20. Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S, et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009; 51: 765-77.
21. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-69.
22. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol 2005; 174: 3137-42.
23. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-75.
24. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009; 133: 157-70.
25. Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J 2005; 52: 519-24.
26. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an Adipocytokine With Pro-Inflammatory and Immunomodulating Properties. J Immunol 2007; 178: 1748-58.
27. Bluher M, Tonjes A, Stumvoll M. Does retinol-binding protein 4 cause or reflect fatty liver disease? Hepatology 2008; 48: 4-6.
28. Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des 2010; 16(17): 1896-901.
29. Procaccini C, Galgani M, De Rosa V, Carbone F, La Rocca C, Ranucci G, et al. Leptin: the prototypic adipocytokine and its role in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16(17): 1902-12.
30. Moschen AR, Gerner RR, Tilg H. Pre-B cell colony enhancing factor/Nampt/visfatin in inflammation and obesity-related disorders. Curr Pharm Des 2010; 16(17): 1913-20.
31. Tönjes A, Blüher M, Stumvoll M. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16(17): 1921-28.
32. Bertolani C, Marra F. Role of adipocytokines in hepatic fibrosis. Curr Pharm Des 2010; 16(17): 1929-40.
33. Bugianesi E, Moscatiello F, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16(17): 1941-51.
34. Cheung O, Sanyal AJ. Role of MicroRNAs in nonalcoholic steatohepatitis. Curr Pharm Des 2010; 16(17): 1952-57.
35. Wilfried de Alwis NM, Day CP. Current and future therapeutic strategies in NAFLD. Curr Pharm Des 2010; 16(17): 1958-62.